Literature DB >> 31868112

Depleting tumor-associated Tregs via nanoparticle-mediated hyperthermia to enhance anti-CTLA-4 immunotherapy.

Hongwei Chen1, Xin Luan1, Hayley J Paholak1, Joseph P Burnett1, Nicholas O Stevers1, Kanokwan Sansanaphongpricha1,2, Miao He1, Alfred E Chang3, Qiao Li3, Duxin Sun1.   

Abstract

Aim: We aim to demonstrate that a local nanoparticle-mediated hyperthermia can effectively eliminate tumor-associated Tregs and thereby boost checkpoint blockade-based immunotherapy. Materials & methods: Photothermal therapy (PTT), mediated with systemically administered stealthy iron-oxide nanoparticles, was applied to treat BALB/c mice bearing 4T1 murine breast tumors. Flow cytometry was applied to evaluate both Treg and CD8+ T-cell population. Tumor growth following combination therapy of both PTT and anti-CTLA-4 was further evaluated.
Results: Our data reveal that tumor-associated Tregs can be preferentially depleted via iron-oxide nanoparticles-mediated PTT. When combining PTT with anti-CTLA-4 immunotherapy, we demonstrate a significant inhibition of syngeneic 4T1 tumor growth.
Conclusion: This study offers a novel strategy to overcome Treg-mediated immunosuppression and thereby to boost cancer immunotherapy.

Entities:  

Keywords:  Tregs; anti-CTLA-4 immunotherapy; immunosuppression; photothermal therapy; tumor microenvironment

Mesh:

Substances:

Year:  2020        PMID: 31868112      PMCID: PMC7132783          DOI: 10.2217/nnm-2019-0190

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  69 in total

1.  Breakthrough of the year 2013. Cancer immunotherapy.

Authors:  Jennifer Couzin-Frankel
Journal:  Science       Date:  2013-12-20       Impact factor: 47.728

Review 2.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

3.  Multimodal imaging guided photothermal therapy using functionalized graphene nanosheets anchored with magnetic nanoparticles.

Authors:  Kai Yang; Lilei Hu; Xingxing Ma; Shuoqi Ye; Liang Cheng; Xiaoze Shi; Changhui Li; Yonggang Li; Zhuang Liu
Journal:  Adv Mater       Date:  2012-02-29       Impact factor: 30.849

4.  Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.

Authors:  Alexander Martens; Kilian Wistuba-Hamprecht; Marnix Geukes Foppen; Jianda Yuan; Michael A Postow; Phillip Wong; Emanuela Romano; Amir Khammari; Brigitte Dreno; Mariaelena Capone; Paolo A Ascierto; Anna Maria Di Giacomo; Michele Maio; Bastian Schilling; Antje Sucker; Dirk Schadendorf; Jessica C Hassel; Thomas K Eigentler; Peter Martus; Jedd D Wolchok; Christian Blank; Graham Pawelec; Claus Garbe; Benjamin Weide
Journal:  Clin Cancer Res       Date:  2016-01-19       Impact factor: 12.531

5.  Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers.

Authors:  Anu Sharma; Sumit K Subudhi; Jorge Blando; Jorge Scutti; Luis Vence; Jennifer Wargo; James P Allison; Antoni Ribas; Padmanee Sharma
Journal:  Clin Cancer Res       Date:  2018-07-27       Impact factor: 12.531

Review 6.  Cancer theranostics with near-infrared light-activatable multimodal nanoparticles.

Authors:  Marites P Melancon; Min Zhou; Chun Li
Journal:  Acc Chem Res       Date:  2011-08-17       Impact factor: 22.384

7.  Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.

Authors:  Emanuela Romano; Monika Kusio-Kobialka; Periklis G Foukas; Petra Baumgaertner; Christiane Meyer; Pierluigi Ballabeni; Olivier Michielin; Benjamin Weide; Pedro Romero; Daniel E Speiser
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

8.  Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism.

Authors:  Jeremy D Waight; Qiang Hu; Austin Miller; Song Liu; Scott I Abrams
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

Review 9.  Combination immunotherapy: a road map.

Authors:  Patrick A Ott; F Stephen Hodi; Howard L Kaufman; Jon M Wigginton; Jedd D Wolchok
Journal:  J Immunother Cancer       Date:  2017-02-21       Impact factor: 13.751

10.  Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer.

Authors:  Jutaek Nam; Sejin Son; Lukasz J Ochyl; Rui Kuai; Anna Schwendeman; James J Moon
Journal:  Nat Commun       Date:  2018-03-14       Impact factor: 14.919

View more
  10 in total

Review 1.  Photothermal therapies to improve immune checkpoint blockade for cancer.

Authors:  Preethi B Balakrishnan; Elizabeth E Sweeney; Anvitha S Ramanujam; Rohan Fernandes
Journal:  Int J Hyperthermia       Date:  2020-12       Impact factor: 3.914

Review 2.  Nanozyme-Based Enhanced Cancer Immunotherapy.

Authors:  Ngoc Man Phan; Thanh Loc Nguyen; Jaeyun Kim
Journal:  Tissue Eng Regen Med       Date:  2022-01-31       Impact factor: 4.169

Review 3.  Advanced iron oxide nanotheranostics for multimodal and precision treatment of pancreatic ductal adenocarcinoma.

Authors:  Lei Zhu; Hui Mao; Lily Yang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2022-04-09

Review 4.  Bacteria as Nanoparticle Carriers for Immunotherapy in Oncology.

Authors:  Víctor M Moreno; Alejandro Baeza
Journal:  Pharmaceutics       Date:  2022-04-03       Impact factor: 6.525

Review 5.  Multifunctional inorganic nanomaterials for cancer photoimmunotherapy.

Authors:  Lu Tang; Aining Zhang; Ziyao Zhang; Qingqing Zhao; Jing Li; Yijun Mei; Yue Yin; Wei Wang
Journal:  Cancer Commun (Lond)       Date:  2022-01-09

Review 6.  Hyperthermia combined with immune checkpoint inhibitor therapy in the treatment of primary and metastatic tumors.

Authors:  Ximing Yang; Miaozhi Gao; Runshi Xu; Yangyang Tao; Wang Luo; Binya Wang; Wenliang Zhong; Lan He; Yingchun He
Journal:  Front Immunol       Date:  2022-08-12       Impact factor: 8.786

7.  CpG-coated prussian blue nanoparticles-based photothermal therapy combined with anti-CTLA-4 immune checkpoint blockade triggers a robust abscopal effect against neuroblastoma.

Authors:  Juliana Cano-Mejia; Anshi Shukla; Debbie K Ledezma; Erica Palmer; Alejandro Villagra; Rohan Fernandes
Journal:  Transl Oncol       Date:  2020-07-08       Impact factor: 4.243

Review 8.  Tumor Targeted Nanocarriers for Immunotherapy.

Authors:  Alejandro Baeza
Journal:  Molecules       Date:  2020-03-26       Impact factor: 4.411

Review 9.  Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy.

Authors:  Chiara Cremolini; Emanuela Vitale; Raffaella Rastaldo; Claudia Giachino
Journal:  Nanomaterials (Basel)       Date:  2021-03-08       Impact factor: 5.076

Review 10.  Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer.

Authors:  Alba Navarro-Ocón; Jose L Blaya-Cánovas; Araceli López-Tejada; Isabel Blancas; Rosario M Sánchez-Martín; María J Garrido; Carmen Griñán-Lisón; Jesús Calahorra; Francisca E Cara; Francisco Ruiz-Cabello; Juan A Marchal; Natalia Aptsiauri; Sergio Granados-Principal
Journal:  Pharmaceutics       Date:  2022-02-25       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.